Table 1.

Treatment and methods summary for animal studies

Study	Genotype	Age at treatment	Animals per arm	Treatments	Administration route	Dose	Schedule	Treatment duration
ARPKD rat, short-term therapeutic intervention	PcK/Crljcrl-Pkhd1pck	4 weeks	10	Vehicle	NA	NA	NA	4 weeks
	PcK/Crljcrl-Pkhd1pck	4 weeks	10	Mozavaptan	i.p.	0.5, 5, 10 mg/kg	Once, every third day	4 weeks
ARPKD rat, Long-term therapeutic intervention	PcK/Crljcrl-Pkhd1pck	4 weeks	10	Vehicle	NA	NA	NA	8 weeks
	PcK/Crljcrl-Pkhd1pck	4 weeks	10	Mozavaptan	Milled chow	0.10%	ad libitum	8 weeks
	PcK/Crljcrl-Pkhd1pck	4 weeks	10	Etanercept	i.p.	5 mg/kg	Once, every third day	8 weeks
ADPKD (PDK2 ws25/-) mouse, therapeutic intervention	PKD2 ws25/-	12 weeks	14	Vehicle	NA	NA	NA	8 weeks
	PKD2 ws25/-	12 weeks	11	Mozavaptan	Milled chow	0.10%	ad libitum	8 weeks
	PKD2 ws25/-	12 weeks	15	Etanercept	i.p.	5 mg/kg	Once, every third day	8 weeks
ADPKD (PDK2 ws25/-) mouse, prophylactic intervention	PKD2 ws25/-	4 weeks	15	Vehicle	NA	NA	NA	8 weeks
	PKD2 ws25/-	4 weeks	15	Mozavaptan	Milled chow	0.05%	ad libitum	8 weeks
	PKD2 ws25/-	4 weeks	15	Etanercept	i.p.	5, 10 mg/kg	Once, every third day	8 weeks